Search Results 51-60 of 16283 for Proto-oncogene
Molecular characterization may include short tandem DNA repeat; STR) and oncogenic/tumor suppressor gene mutation analyses to assure that the derived models ...
The purpose of this study is to evaluate nab-paclitaxel as maintenance therapy after cisplatin-based chemotherapy and surgery in treating patients with ...
Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, ...
Oncogenic osteomalacia, also referred to as tumor-induced osteomalacia (TIO), is a rare disorder characterized by urinary phosphate wasting due to an ...
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...
Guidance for molecular targeted therapy will involve gene analysis of oncogenes and tumor suppressor genes. Results from these studies may provide the ...
... oncogenes frequently affected in lung cancers. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most ...
Cancer disparities · Cancer stem cells · Cancer systems biology · Oncogenic gene dysregulation and carcinogenesis · Precision cancer medicine and translational ...
Overview · Describing a paradigm shift for the tumor suppressor FoxO3a, whereby our research team identified a new oncogenic role promoting tumor growth ...
* Subjects on prior intravenous therapy (e.g., chemotherapy or checkpoint inhibitors), or prior oral therapy (e.g.,proto-oncogene B-RAF or mitogen-activated ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.